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Abstract
Prostate cancer remains the most common malignancy among men in United States, and there is no remedy currently
available for the advanced stage hormone-refractory cancer. This is partly due to the incomplete understanding of
androgen-regulated proteins and their encoded functions. Whole-cell proteomes of androgen-starved and androgen-
treated LNCaP cells were analyzed by semi-quantitative MudPIT ESI- ion trap MS/MS and quantitative iTRAQ MALDI- TOF
MS/MS platforms, with identification of more than 1300 high-confidence proteins. An enrichment-based pathway mapping
of the androgen-regulated proteomic data sets revealed a significant dysregulation of aminoacyl tRNA synthetases,
indicating an increase in protein biosynthesis- a hallmark during prostate cancer progression. This observation is supported
by immunoblot and transcript data from LNCaP cells, and prostate cancer tissue. Thus, data derived from multiple
proteomics platforms and transcript data coupled with informatics analysis provides a deeper insight into the functional
consequences of androgen action in prostate cancer.
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Introduction
Cancer of the prostate (PCa) is the most commonly diagnosed
cancer among men in the United States, with an estimated
200,000 new cases and 29,000 deaths for 2008 [1]. Many reports
suggest that androgens which are required for normal develop-
ment of the prostate also support the growth and progression of
PCa. Androgens exert their cellular effects via binding to the
androgen receptor (AR), a member of the nuclear hormone
receptor (NR) super family. AR, in turn, binds to androgen
response elements (AREs) in the promoter and enhancer regions of
target genes, acting as a transcriptional regulator by transducing
the cognate hormone signal in the nucleus [2,3]. Prostate cancer
therapy through androgen ablation initially achieves regression of
tumors; however, a more aggressive, hormone-refractory form of
the tumor (HR-PCa) may evolve, with subsequent mortality.
Although multiple groups have interrogated androgen-regulated
changes at the transcriptome and proteome levels using gene
expression arrays and mass spectrometry, respectively
[4,5,6,7,8,9,10], there is still a lack of considerable understanding
on the functional consequence of the hormone action during
prostate cancer development. Partly this deficiency is a reflection
of the sparseness in the proteomic data; due to the limitations of
proteomic technologies, the total number of proteins identified and
quantified in a single study is modest. In addition, there are
technical challenges from such under-representation of proteins
and in assessing the statistical significance of differences in protein
expression.
To overcome these challenges, and to obtain a deeper insight
into androgen-regulated proteomic alterations in prostate cancer,
we applied a two-pronged strategy. First, we enhanced the breath
of the androgen-regulated proteome profiled in this study by
employing two complementary mass-spectrometry (MS) platforms:
one that involves isotope labeling of peptides with an iTRAQ
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7075reagent followed by 2D liquid chromatography (LC) MALDI-
TOF MS/MS analysis on an ABI 4800 MALDI tandem time-of
flight (TOF/TOF) instrument [11] and the other a label-free
approach based on spectral counting [12,13,14,15] using Multi-
dimensional Protein Identification Technology (MudPIT) [16]
with Electrospray Ionization (ESI)- ion trap MS/MS on a linear
ion trap (LTQ) instrument. Second, we elucidated the proteomic
alterations in the context of functional pathways using Molecular
Concepts Mapping (MCM, also called Oncomine Concepts
Mapping (OCM)) [17], to gain deeper insight into the biology of
androgen action in prostate cancer. Notably, such combinatorial
analyses revealed a striking increase in the level of aminoacyl
tRNA synthetases (aaRS) that could underlie the increase in
protein biosynthesis predicted in prostate cancer by various gene
expression studies.
Results
We employed an integrative strategy (Figure 1) to understand
androgen action in prostate cancer. In brief, we performed mass
spectrometry-based proteome profiling of androgen-deprived and
androgen-stimulated LNCaP cells. Trypsin-digested proteins were
identified and quantified using two mass spectrometric platforms:
iTRAQ MALDI-TOF MS/MS and MudPIT ESI- ion trap MS/
MS. The data from each of these platforms were normalized
independently and combined to generate a list of androgen
regulated proteins. The androgen regulated proteome was
interrogated for biological associations using Molecular Concepts
Mapping (MCM). From the many molecular concepts, including
the androgen-regulated and prostate cancer concepts that were
enriched by our androgen up-regulated data set, the concept
describing elevated aminoacyl tRNA synthetases (aaRSs) was
selected for further examination. A subset of these proteins was
validated by immunoblot analysis. Using transcriptomic profiling
and chromatin immunoprecipitation, we showed that androgen
drives the expression of aaRSs at the transcript level. Finally, we
showed the existence of the elevated aaRS niche during prostate
cancer progression using clinical specimens.
Identification and relative quantitation of LNCaP proteins
by iTRAQ MALDI-TOF MS/MS
Using iTRAQ MALDI-TOF MS/MS platform, we identified
904 proteins with high confidence scores as determined with
SEQUEST [18], PeptideProphet [19] and ProteinProphet [20]
computational tools. Of these, 879 were quantified post-data
normalization (Figure 2A), with the overall protein identification
FDR of less than 1 % (see Materials and Methods for detail).
Procedurally, the androgen proteome was assessed by iTRAQ
using two independent biological replicates. A double duplex
iTRAQ experiment was carried out wherein androgen-treated
samples in each replicate were labeled with the 115 and 117
isobaric tags while their corresponding control samples were
labeled using the 114 and 116 isobaric tags. In order to derive a
threshold to define protein expression changes, we normalized the
relative protein ratio for each of the androgen-treated samples and
one of the controls (labeled with isobaric tag 116) to the protein
expression in the control sample labeled with the 114 isobaric tag.
The distribution of all protein ratios for the androgen-treated
sample (tag 115) versus control (tag 116) is shown in Supplemen-
tary Figure S1A. More than 80% of proteins had ratios within the
range of 0.8–1.2. The median-centered normalization resulted in a
mean close to unity for all samples, and the standard deviation of
the control replicate (tag 116, SD=0.16) was used as a scale to set
the threshold ratio for differentially expressed proteins. Accord-
ingly, changes with a minimum threshold of 1.25 SD (ratio of 1.2
for up-regulated and 0.83 for down-regulated) were considered as
significant (see Materials and Methods for details). The lists of all
70 androgen up-regulated and 39 down-regulated proteins
identified from this analysis are given in Supplementary Table
S1 and Supplementary Table S2, respectively.
Semi-quantitative comparison of proteins using MudPIT
analysis
Using MudPIT ESI- ion trap MS/MS proteomic profiling
approach 857 proteins were identified with the minimum protein
probability score of 0.9 (estimated FDR of less than 1%); 67%
(574) of them were identified in common between control and
androgen-treated samples, while 126 proteins and 157 proteins
were identified only in control and androgen-treated samples,
respectively (Figure 2B). In addition to determining the presence
or absence of proteins, we performed a statistical analysis to
compare the relative spectral counts for proteins in each
treatment. The total number of spectra from either control or
androgen-treated data was independently normalized, and the
normalized cumulative spectral counts of all the peptides for each
protein were used as a measure of protein abundance. Based on
the statistical analysis of data, proteins were designated as
differentially expressed if they were identified only in either the
control (down-regulated) or androgen treated sample (up-regulat-
ed) with four or more peptides. For proteins identified in both
samples, normalized spectral count ratios of two standard
deviations above or below the mean of all proteins in that group
(which corresponds to a four-fold change) was used as cut-off (see
Materials and Methods; see Supplementary Figure S1B for
distribution of the normalized spectral count ratios for proteins
identified in control and androgen-treated samples). Based on
these criteria, 65 and 57 proteins were designated as androgen up-
regulated and down-regulated, respectively (Supplementary Table
S3, Supplementary Table S4).
Combined list of differentially expressed proteins
identified from the two MS platforms
With the understanding that the list of peptides profiled by mass
spectrometry is influenced by the ionization source and the mass
analyzer [21] (in this case MALDI- TOF vs. ESI-ion trap), we
combined the protein lists derived from the two MS platforms to
derive a composite list. This was facilitated by the fact that the two
platforms identified similar numbers of high confidence proteins
(857 and 879 proteins from MudPIT and iTRAQ, respectively,
with comparable FDR of less than 1 %). As a first step in the
process, non-redundant proteins were culled from each experi-
ment by converting their IPI accession numbers to gene IDs.
Three proteins (lectin, mannose-binding 2, LMAN2; CLPX,
caseinolytic peptidase X homolog; and 40S ribosomal protein S9,
RPS9) that showed discordant trends in their expression between
the two platforms were removed. These procedures yielded a total
of 844 and 875 proteins, respectively, for MudPIT and iTRAQ
data sets (Figure 2B, 2A). Together 1306 proteins were observed in
the combined dataset (Figure 1 and Figure 2C). Of these, 126
unique proteins were elevated upon androgen treatment. Notably,
9 of these androgen-up regulated proteins overlapped between the
two proteomic platforms (Figure 2D): KLK3, ACSL3, FASN,
FKBP5, AARS (alanyl-tRNA synthetase), FDFT1 (farnesyl-
diphosphate farnesyltransferase 1), UAP1 (UDP-N-acteylglucosa-
mine pyrophosphorylase 1), ENDOD1 (endonuclease domain
containing 1), and NDRG1. The combined down-regulated list
contained 95 proteins, and one (HNRPL, heterogeneous nuclear
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PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7075ribonucleoprotein L isoform a) was common between iTRAQ and
MudPIT platforms (Figure 2E).
Our list of up-regulated proteins included five proteins that have
been shown previously to be elevated by androgen action: ACSL3
(iTRAQ ratio 2.76), FKBP51 (iTRAQ ratio 1.91; MudPIT
spectral counts 17:0), FASN (iTRAQ ratio 1.85; MudPIT spectral
counts 417:45), NDRG1 (iTRAQ ratio 1.76; MudPIT spectral
counts 5:0), and KLK3 (also known as PSA, Prostate Specific
Figure 1. Outline of the strategy employed in this study (see text for details). Androgen-stimulated LNCaP cells were profiled using both
quantitative iTRAQ MALDI- TOF/TOF and semi-quantitative MudPIT ESI- LTQ proteomics platforms. Data from each of these platforms were
normalized independently and combined to generate a list of androgen-regulated proteins. This list was interrogated for biological associations using
Molecular Concepts Mapping (MCM). The concept describing aminoacyl tRNA synthetases was selected for further examination; selected proteins
were validated using immunoblot and immunofluorescence staining. Transcriptomic profiling and chromatin immunoprecipitation showed that
androgen drives expression of aminoacyl-tRNA synthases at the transcript level. This was further confirmed using cancer tissue gene expression data
and immunoblot analysis on prostate tissue samples, which demonstrated the existence of the elevated aminoacyl-tRNA synthase niche during
prostate cancer progression.
doi:10.1371/journal.pone.0007075.g001
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quantitative comparison of proteins identified on both the MS
platforms showed a high positive correlation (Rˆ2=0.92) for three
proteins (ACSL3, FASN, and AARS; see Supplementary figure
S1). These findings independently validated our normalization
procedure and the thresholds that were used to build the
combined list of androgen-regulated proteins. Further, immuno-
blot analysis was employed to confirm the androgen-regulation of
a subset of up-regulated proteins (Figure 3A). Notably, in addition
to validating our mass spectrometry results, the immunoblot
analysis revealed significant compression in the fold change of
protein expression delineated by iTRAQ experiment (Figure 3A).
A similar orthogonal verification performed for the androgen up-
regulated protein fatty acid synthase by immunofluorescence-
microscopy is shown in Figure 3B.
Analysis of androgen up-regulated biological processes
and pathways by MCM analysis
To gain insight into the functional consequence of androgen-
action, A large-scale association analysis was performed comparing
our androgen up-regulated protein data set of 126 proteins with each
of the 13364 concepts in the MCM [23]. The procedure involved in
selection of significant molecular concepts is described in ‘Materials
and Methods’section. The enrichment networkresulted inthe MCM
analysis with the combined set of androgen up-regulated proteins is
presented in Figure 4. Importantly, the analysis showed enrichment
Figure 2. Total and androgen-regulated proteins identified from two mass-spectrometric platforms. A) Venn diagram showing the
number of total and the sub-sets of androgen-regulated proteins identified from iTRAQ MALDI TOF- MS/MS analysis. A minimum threshold of 1.25 SD
from the global mean in both androgen-treated samples and not less than 1.5 SD in one of the androgen treated samples was set. B) Venn diagram
showing the numbers of total and androgen-regulated LNCaP proteins identified in MudPIT (ESI ion trap- MS/MS) analysis. Proteins shown in brackets
were not considered for differential analysis because of their lower spectral counts. C) Venn diagram showing the total number of proteins identified
from two mass-spectrometric platforms and their overlap. D) Venn diagram showing the total number of androgen up-regulated proteins identified
from two mass-spectrometric platforms and their overlap. E. Venn diagram showing the total number of androgen down-regulated proteins
identified from two mass-spectrometric platforms and their overlap.
doi:10.1371/journal.pone.0007075.g002
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thus providing a validation of the proteomic data generated in this
work (Figure 4, red colored edges). Nested within these previously
known prostate-specific concepts was one that described a set of co-
enriched genes down-regulated in prostate cancer patients after post-
neoadjuvant (anti-androgen) therapy [17]. Additional concepts of
significance included those for aminoacyl-tRNA biosynthesis and ER
to Golgi transport (both GO biological process), aminoacyl-transfer
RNA synthetase Class II (InterPro), and RSRFC4 (MEF2A) and
NKX3A (both Transfac). We were intrigued by those concepts that
referred to aminoacyl tRNA synthetases (KEGG pathway: http://
www.genome.jp/kegg/ [24,23]), as they potentially reflect an
elevation in amino acid utilization and thus an increase in
downstream protein biosynthesis upon androgen treatment
(Figure 4, blue colored edges). This observation is in agreement with
our earlier gene expression-based prediction of increased protein
biosynthesis as one of the hallmarks during prostate cancer
development [17]. Elevated aaRS activity was also among the
significant concepts enriched by matched transcriptome data for
androgen treated LNCaP cells (data not shown). Thus, such
observations led us to select the aminoacyl tRNA synthetase concept
for further analyses.
Androgen regulation of aminoacyl tRNA synthetases
There were 7 proteins in the aaRS category that exceeded the
set threshold in the combined list of proteins defined using both
MS platforms: aaRS for alanine (AARS), phenylalanine (FAR-
SLA), glycine (GARS), histidine (HARS), asparagine (NARS),
threonine (TARS) and tryptophan (WARS). Of these only AARS
and HARS were nominated by the MudPIT platform (Table S3)
while AARS and the rest were nominated by the iTRAQ study
(Table S1). Although, the total numbers of aaRS identified in
iTRAQ and MudPIT experiments were 14 and 13, respectively,
several of these proteins were identified with less than four peptides
in MudPIT experiment making it less reliable for their spectral
count based quantitation. This also indicates the low abundant
nature of this critical class of proteins. Therefore, we focused to
further analyze the iTRAQ identified aaRSs and examined if
there is compression in expression ratio despite their elevated
expression. Of the 14 aaRSs identified in the iTRAQ study, six
had iTRAQ ratios 1.2 and above, and three of them had ratios 1.1
and above in both androgen-treated (115 and 117) replicate
samples. Over-expression of majority these (nine of 14) aaRSs is
depicted in a heat map (Figure 5A). A subset of these iTRAQ
identified aaRSs (GARS, KARS, and WARS) were validated
using androgen-treated LNCaP cells by immunoblot analysis
(Figure 5C). Further, we examined their transcript levels using
matched gene expression data for androgen-treated LNCaP cells
(see Materials and Methods section). Nine of the fourteen proteins
identified by our protein profiling were elevated at the transcript
level across independent gene expression experiments (Figure 5B).
This revealed potential regulation of these proteins by transcrip-
tional activation by androgen. These data also support the
observation of compression in fold change of protein expression
in iTRAQ ratios.
Androgens mediate their positive effect on transcription by
binding to androgen receptor, which in turn binds to androgen
response elements on the promoters of target genes [25]. Thus, we
proceeded to examine androgen binding to the promoters of
aminoacyl tRNA synthetases using chromatin immunoprecipita-
tion (ChIP, see Materials and Methods). Figure 5E shows
representative example of increased occupancy of AR on the
promoter of GARS and KARS confirming androgen regulation of its
expression at the transcript level.
We next extended our cell line observation to prostate cancer
tissue specimens. First, we used the ONCOMINE database (www.
oncomine.org) to perform a meta-analysis for aminoacyl tRNA
synthetase transcripts across multiple prostate cancer studies [26].
A subset of aaRSs was found to be up-regulated in localized
prostate cancer samples in more than one study (Figure 5F). This
observation was confirmed using immunoblot analysis of prostate-
derived samples that included benign adjacent, localized prostate
cancer, and metastatic disease. Importantly, four of the five
localized PCa and four of the five metastatic PCa showed elevated
expression of KARS and GARS when compared to three of the
four benign samples tested (Figure 5D). These lend credence to a
possible role of androgen-regulated aminoacyl tRNA synthetases
action during prostate cancer progression.
Discussion
To delineate the biological processes and pathways that are
dysregulated by androgen in prostate cancer, we adopted a
strategy of global MS-based proteomic profiling coupled to
enrichment-based pathway mapping in the androgen-responsive
prostate cancer cell line LNCaP. We profiled the proteome of
LNCaP cells with and without androgen treatment using two
Figure 3. Androgen-induced expression of LNCaP proteins. A)
Expression fold change of androgen-regulated proteins in mass-
spectrometric quantitation compared to immunoblot assessment.
Shown are the immunoblot bands and their intensities for androgen
up-regulated proteins and their calculated intensity ratios as well as
iTRAQ ratios and MudPIT spectral counts for the corresponding
proteins. Beta-tubulin is used as a sample loading control. B)
Immunofluorescence staining of AR (Red) and FASN (Green) following
vehicle (ethanol) and 1 nM R1881 treatments for 48 h on LNCaP cells.
Treatment was given after 48 h of androgen deprivation.
doi:10.1371/journal.pone.0007075.g003
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semi-quantitative MudPIT Ion Trap MS. Each of the platforms
independently identified in excess of 850 high confidence proteins,
yielding a total of 1306. The gain in cumulative protein counts is
consistent with earlier reports describing the advantage of
interrogating global proteomes using complementary mass spec-
trometry platforms [21,27]. We were able to identify 126 proteins
that were up-regulated upon androgen treatment. Included were
known targets of androgen action: KLK3, FKBP5, FASN, AGR2
(anterior gradient homolog 2), SORD (sorbitol dehydrogenase),
NDRG1, ACSL3 and FOLH1 (folate hydrolase 1). Additionally,
nested in the compendia of differentially regulated proteins, were
novel targets of androgen action that included PCID1 (PCI
domain containing 1), RAB10 (ras-related GTP-binding protein
RAB10), and PEA15 (phosphoprotein enriched in astrocytes 15).
An additional advantage of using the ion trap- based profiling
strategy in tandem with TOF-TOF based quantitative profiling
was that data from the former helped offset the loss of resolution
resulting from iTRAQ ratio compression seen in the latter. This
permitted the use of lower threshold level from iTRAQ-based
quantitation for perturbation analysis. The ratio compression has
been widely reported by others, e.g. [28], and is well illustrated by
the direct comparison of iTRAQ ratios for androgen-regulated
proteins with the corresponding expression as assessed by
immunoblot analysis (Figure 3). As an example, protein FASN
was identified with 17 peptides; among them the most differen-
tially expressed peptide had an iTRAQ ratio of 2.79. Notably,
averaging all iTRAQ ratios for 17 peptides resulted in a further
compressed protein iTRAQ ratio of 1.85, while densitometry-
based analysis of its expression by immunoblot revealed fold
Figure 4. Molecular concepts of androgen up-regulated proteins from two mass spectrometry platforms. Network view of molecular
concepts or sets of biologically related genes enriched in androgen up-regulated protein set obtained through Molecular Concepts Mapping (MCM)
analysis. Each node represents a biological concept; the node size is proportional to the number of genes in each concept. Each edge represents a
statistically significant enrichment. P-value of each concept and the MCM number of the concept are given in brackets. The most enriched concept is
indicated by a thick edge. Red colored edges indicate enrichment of known prostate cancer-specific and androgen-regulated concepts.
Interconnected aminoacyl tRNA synthetase concepts are indicated in blue edges at the bottom of the network.
doi:10.1371/journal.pone.0007075.g004
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7075Figure 5. Androgen dependent up-regulation of aminoacyl tRNA synthetases in LNCaP, and their expression in prostate cancer. A)
Heat map showing the elevated expression of aminoacyl-tRNA synthetases identified from iTRAQ experiment. Only proteins in bold face are designated
as androgen up-regulated in the iTRAQ data based on the threshold cut-off used. B) Heat map showing the concordant over-expression of transcripts
measured using oligonucleotide microarray (Affymetrix U133 Plus 2.0) for aminoacyl-tRNA synthetases shown in A. C) Immunoblot analysis of aminoacyl
t-RNA synthetases GARS, KARS, and WARS in response to androgen treatment in LNCaP cells. Beta-tubulin is used as loading control. D) Immunoblot
analysis of KARS and GARS in localized prostate cancer (PCa), and metastatic prostate cancer (Met) compared to normal (benign) prostate tissues. Beta-
actin is used as loading control. E) Promoter-occupancy of AR onaminoacyl tRNA genes. Chromatin immunoprecipitation (ChIP)-PCR analysis showsthe
androgen-dependent enrichment of AR-binding to the target promoters of GARS and KARS. Enrichment ratio was calculated based on the amount of
target amplification against the input DNA, with primers for GAPDH promoter used as control. The primer sequences spanning the gene promoters are
given in Table S5. F) Meta-analysis of the aminoacyl t-RNA synthetase genes (of proteins shown in A) across three prostate cancer gene expression
profiling studies. Oncomine heat map view showing the over-expression of a subset of aminoacyl-tRNA synthetase genes in localized prostate cancer
compared to their benign controls. Gene symbols of proteins that pass through the cut-off value andwere assigned as androgen up-regulated in iTRAQ
data are indicated in bold face. P-value represents the significance of expression in two of the three studies. Red, white, and blue (not present in the
figure) indicates relative over, unchanged, and under expression, respectively.
doi:10.1371/journal.pone.0007075.g005
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a highly elevated expression. This conclusion is supported by the
spectral counting of the MudPIT data, wherein FASN was
represented by 417 spectra in the androgen-treated sample
compared to only 45 spectra in the control sample. Such ratio
compression, although seen in other studies, was more prominent
in our iTRAQ MALDI- TOF/TOF data compared to other
quantitative MS platforms such as ICAT [9]. This difference may
be explained by a wider mass tolerance window for selection of
peptide ions for MS/MS fragmentation in the ABI 4800 TOF/
TOF mass analyzer used here [29]. We believe that this
compression in ratio could partly explain the poor overlap
between the sets of androgen-regulated proteins nominated from
each of the two MS platforms. Additionally, factors such as
differences in peptide processing (labeled versus unlabeled),
peptide fractionation (on-line and offline), MS data acquisition
(ion trap versus TOF/TOF mass analyzer), data normalization
(ratios of spectral counts versus ratios of iTRAQ label peak
intensities), and the properties of peptides selected for MS/MS
sequencing could play pivotal roles in the lack of global
concordance. These factors, in addition to the biological variations
such as the multiple splice forms for a single accession could also
have contributed to those three proteins that showed discordant
trends between the two platforms observed.
Indeed, it has been established that different proteomic
platforms show substantial differences in the physico-chemical
properties of the identified peptides [30]. Thus, the strategy of
using two different mass spectrometers, which differ both in their
ionization source and principle of peptide detection, allowed us to
build an additive list of proteins and gain deeper insight into the
androgen-regulated proteome. With higher level enrichment
analyses, our study showed that subsets of proteins, nominated
by each of the two platforms, map to similar concepts including
those that are androgen-derived and prostate cancer-derived. With
a stringent threshold setting for the spectral count based semi-
quantitation, the MudPIT experiment had nominated only two
aaRSs candidates as androgen regulated. However, due to the
nomination of higher number of aaRSs from iTRAQ experiment,
molecular concept network with combined data set showed a set of
interconnected aaRS concepts with significant scores (Figure 4).
Even more intriguing, however, was that each of the two
independent lists of proteins, when analyzed separately using
MCM analysis, enriched for concepts that were known to be
associated with prostate cancer progression but were not identified
in the analysis of the combined dataset (Figure 4, Supplementary
Figure S2). An example of this was the enrichment of ETS (ETV1
and ERG) over-expression concepts by the androgen-regulated
proteins nominated by MudPIT analysis. This was interesting in
the context of earlier reports that describe the existence of
recurrent gene fusions involving ETS transcription factors to be
pathonomonic to prostate cancer development [31,32]. These
gene fusions have been shown to bring ETS transcription factors
under androgen control, and ETV1 (chromosome 7p21) is known
to be over-expressed by androgen through its rearrangement to
14q13.3–14q21.1 region of chromosome 14 in LNCaP cell line
studied here [31]. As the number of ETS regulated proteins
identified in MudPIT was sufficient to map the ETS over-
expression concept, lack of similar proportion of this class of
proteins in iTRAQ platform possibly resulted in the disappearance
of the same concept in the combined analysis. Thus, use of
multiple mass spectrometric platforms helps to elucidate multiple
roles of androgen action.
In addition to previously known androgen-regulated biological
processes associated with prostate cancer progression, such as
NDRG1 [33] that helped to validate our proteomic study, our list
of androgen-regulated proteins was enriched for aminoacyl tRNA
synthetases. Several aaRSs that are known to play a pivotal role in
protein biosynthesis were included in this concept. This finding
was interesting in the context of earlier gene expression-based
predictions from our laboratory: an increase in protein synthesis
during prostate cancer progression driven by actions of ETS
transcription factors [17]. These observations lead us to the
validation of this finding at multiple levels; starting at the level of
regulatory controls with a combination of matched gene
expression and chromatin immunoprecipitation assays. Finally,
we used Western for orthogonal verification of the MS findings on
the LNCaP cells, and showed that indeed the class of aaRSs are
altered both at the transcript and protein level in prostate cancer.
Materials and Methods
Materials
Synthetic androgen R1881 (methyltrienolone) was purchased
from Perkin Elmer (Boston, MA). A 10 mM R1881 stock was
prepared in 100% ethanol and stored in 220uC. RPMI 1640
medium and fetal bovine serum was purchased from Invitrogen
(Carlsbad, CA). Sequencing grade modified trypsin was from
Promega (Madison, WI). Sample preparation reagents formic acid,
trifluoroacetic acid, and HPLC solvents were from Fisher
Scientific (Waltham, MA). Mass spectrometriy grade water was
from Burdick and Jackson (Muskegon, MI, USA). Antibodies used
were: KLK3 (kallikrein 3, rabbit polyclonal, DakoCytomation
Carpinteria, CA ), NDRG1 (N-myc downstream regulated 1, goat
polyclonal, Santa Cruz Biotechnology Inc., Santa Cruz, CA.),
FASN (fatty acid synthase, mouse monoclonal, BD Transduction
Labs, Franklin Lakes, NJ), FKBP5 (FK506 binding protein 5,
mouse monoclonal, BD Transduction Labs), AR (mouse mono-
clonal-AR441, Lab Vision, Fremont, CA), GARS (glycyl-tRNA
synthetase, rabbit polyclonal, Abcam, Cambridge, MA), WARS
(tryptophanyl-tRNA synthetase, rabbit polyclonal, Abcam), KARS
(lysyl-tRNA synthetase, rabbit polyclonal, Bethyl Laboratories,
Montgomery, TX), b-tubulin (rabbit polyclonal, Santa Cruz), b-
actin (rabbit polyclonal, Cell Signaling Technology, Inc., Danvers,
MA). LNCaP cells were purchased from American Type Culture
Collection (University Boulevard, Manassas, VA). Prostate spec-
imens comprising adjacent normal, localized prostate cancer, and
metastasis tissue utilized for immunoblot experiments were from
the University of Michigan Rapid Autopsy Program which is part
of University of Michigan Prostate Cancer Specialized Program of
Research Excellence (SPORE) tissue core.
Cell culture and sample preparation
LNCaP (ATCC number: CRL-1740
TM) cells were grown to
70% confluence in RPMI 1640 medium containing 10% FBS
under 5% CO2 and 90% humidity. Phenol-red free RPMI 1640
supplemented with charcoal-stripped FBS was used to deplete
endogenous androgen for two days. R1881, solubilized in ethanol,
was added at a final concentration of 1 nM for 48 h, and ethanol
was used as vehicle control in parallel experiments. Cells were
washed with tris-buffered saline (TBS) and harvested using a cell
scraper. MudPIT: cells were lysed in RapiGest
TM SF cell lysis
buffer as per the manufacturer’s procedure (Waters Corporation,
Milford, MA). Protein concentrations in the supernatant were
estimated using Bradford assay (BioRad Laboratories, Hercules,
CA). Proteins were reduced using 2 mM tris(2-carboxyethyl)
phosphine hydrochloride at 60uC and alkylated by 5 mM
Iodoacetamide at 37uC. Sequencing grade trypsin (Promega,
Madison, WI), at the ratio of 1:50, was added for digestion over-
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lysed in a lysis solution containing 7 M urea, 2 M thiourea and
100 mM n- octyl-b-D-glucopyranoside, then mixed by intermit-
tent vortexing over 20 min at room temperature, followed by
centrifugation at 12000 RPM for 15 min. Protein concentrations
in the supernatant were estimated using Bradford assay (BioRad
Laboratories) and subjected to acetone precipitation before
digestion. A 100 mg aliquot from each sample was used for the
precipitation. Digestion and labeling using isobaric reagents
(iTRAQH Reagents Multiplex Kit, Applied Biosystems, Foster
City, CA) were performed following the protocol described
previously [28]. Eighty micrograms each of these biological,
duplicate control samples and R1881-treated samples were labeled
with different isobaric tags (114: control_1, 116: control_2, 115:
R1881_1, 117: R1881_2). All four samples were combined and
subjected to fractionation by SCX and RP-LC MALDI plating.
Mass-spectrometry
Online 2D LC-MS/MS (MudPIT) of non-labeled tryptic
peptides using LTQ. Paradigm MG4 HPLC system (Michrom
Bioresources, Inc., Auburn, CA) was used for the separation of the
peptides through a strong cation exchange trap and a reverse
phase C18 microtrap (Michrom Bioresources, Inc.). Progressively
increasing concentrations of ammonium formate (1.75 mM to
500 mM) were used for stepwise elution, and the trapped peptide
salts at the microtrap were washed with buffer A (5% ACN,
0.0025% HFBA, 95% H20). The peptides were eluted using a 60
minute gradient starting with 5% ACN to 70% ACN with a two
buffer system (Buffer A: as above; Buffer B: 95% ACN, 0.0025%
HFBA, 5% H2O). The C-18 microtrap was coupled to an
analytical C-18 column with a pulled tip (75 mm i.d., 10 cm
length; New Objective Inc, Woburn, MA). Peptides were sprayed
directly into the LTQ Mass Spectrometer (Thermo Fisher
Corporation, Waltham, MA).
Equal amounts of proteins (7.5, 15, and 50 mg each) from either
control or R1881-treated LNCaP cells were trypsinized as
described above and purified using a desalting peptide macrotrap
(Michrom Bioresources, Inc.) prior to online SCX and C18
separation. LC-MS/MS was performed for each sample in data
dependent mode using Xcalibur software (Thermo Fisher
Corporation). Each MS full scan (m/z=400–2000) was collected
with an average of 10 micro scans, and the three most abundant
ions were subjected to fragmentation (MS/MS). Collision energy
was set to 30% and with dynamic exclusion duration of 3 minutes.
Offline 2D LC-MS/MS of iTRAQ labeled peptides. SCX
fractionation. Four iTRAQ-labeled samples were combined
and fractionated on 2 sulfoethyl aspartamide SCX spin columns
(SEM HIL-SCX, PolyLC, The Nest Group, Inc. Southboro, MA)
equilibrated with 10 mM KH2PO4, (pH 4.5), 20 % ACN and run
in parallel. Peptides were eluted with 50 ml each of 14 salt steps (35
to 500 mM KCl) and the paired eluates were combined and dried.
RP LC MALDI: A Zorbax 300SB-C18 (3.5 um, 15060.1 mm)
column was used to fractionate each of the above listed fractions.
A 90 min gradient method with a flow rate of 0.4 ml/min was
employed (1100 series nanoflow LC system, Agilent Technologies,
Santa Clara, CA). Column effluent was mixed (micro Tee, Agilent)
with matrix (2.5 mg/ml a-CHCA and 10 mM NH4H2PO4 in
methanol: isopropanol: ACN: H2O: acetic acid (14:30:22:33:0.6)
delivered with an infusion pump (PHD200, Harvard Apparatus,
Holliston, MA) at 0.9 ml/min and directly spotted (microFC,
Agilent) at 0.42 min intervals onto a stainless steel MALDI target
plate from 12 to 92 minutes (192 wells/plate, Applied Biosystems,
Foster City, CA). MALDI- TOF MS/MS analysis: Data were
acquired using 4800 Proteomics Analyzer -TOF/TOF
TM
(Applied Biosystems) linked to 4000 Series Explorer software (v.
3.0). Spectra from m/z 800–3500 were acquired using 750 laser
shots. Spectra with signal to noise (S/N) of 120 were selected for
MS/MS by applying 750–6000 laser shots. Atmospheric gas was
used as the collision gas with a pressure of ,6610
-7 Torr and
collision energy of 1 kV. A seven point Gaussian smoothing and
S/N of 15 were applied using cluster area S/N optimization for
peak detection. Instrument default calibration was updated using
monoisotopic masses for angiotensin I (m/z 1296.685), Glu1-
fibrinopeptide B (m/z 1570.677), ACTH (18–39) (m/z 2465.199),
des-Arg1-bradykinin (m/z 904.468), ACTH (1–17) (m/z
2093.087) and ACTH (7–38) (m/z 3657.923) (ABI).
RNA Isolation and Microarray Analysis
Total RNA isolation was performed using TRIZOL reagent per
the manufacturer’s instructions (Invitrogen). Briefly, cells were
washed with PBS (Phosphate buffer saline) and scraped in
TRIZOL reagent. Approximately 250 ml of chloroform was added
to 1 ml of sample and mixed by inversion. The sample was
centrifuged at 13,000 rpm for 15 min at 4uC. Approximately
500 ml of isopropyl alcohol was added to supernatant and
centrifuged at 13,000 rpm for 15 min at 4uC. The pellet was
washed with 70% ethanol, and centrifuged at 13,000 for 10
minutes at 4uC. After ethanol removal, RNA was dried and
dissolved in RNAse- and DNAse-free water. The RNA was
subsequently purified using RNeasy mini kit (QIAGEN Inc.,
Valencia, CA). The amount and integrity of purified RNA was
checked by NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and Agilent Bioanalyzer (Agilent
Technologies). Total RNA from the individual samples was
analyzed on Affymetrix U133 Plus 2.0 arrays (Affymetrix, Inc.,
Santa Clara, CA). Complementary DNA synthesis, cRNA
synthesis, hybridization, washing, and scanning were done
following the manufacturer’s protocols (Affymetrix, Inc.). The
experimental details and raw data have been deposited in the
NCBI Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo) and are accessible through GEO Series accession
number GSE17044.
Mass-spectrometry data analysis
MudPIT ESI- Ion Trap MS/MS. Raw files were converted
into mzXML files and peptides were assigned to MS/MS spectra
using SEQUEST [18] search against the Human IPI database
version 3.24. The following search parameters were selected: 3 da
precursor mass tolerance, average mass, semi-tryptic search with
two or fewer missed cleavages, and oxidized methionine as a
variable modification. In total, 120290 search results were
obtained in the R1881 treated data set (32178, 47810, 39793,
and 509 assignments to spectra of 1+,2 +,3 +, and 4+ charged
peptide ions, respectively) and 113925 in the control data set
(31643, 44,772, 36699, and 811 assignments to spectra of 1+,2 +,
3+, and 4+ charged peptide ions, respectively). Peptide
assignments were validated using PeptideProphet [19], and the
protein inference performed using ProteinProphet [20], as these
tools are freely available as a part of the Trans-Proteomic Pipeline
(www.proteomecenter.org). The list of protein identifications was
filtered using a 0.9 probability threshold, which corresponds to less
than 1% estimated false discovery rate (FDR). MS/MS data sets
acquired on control and R1881 treated LNCaP cells were
analyzed separately, resulting in 670 and 660 protein groups in
each set (with indistinguishable protein accession numbers
collapsed into a single group), respectively.
iTRAQ MALDI- TOF MS/MS analysis. MS/MS spectra
were extracted from the raw data in Mascot Generic File format
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proteomecommons.org). The mzXML files were searched using
SEQUEST against the Human IPI database version 3.24
appended with an equal number of decoy sequences (reversed
sequences from the original database). The following search
parameters were selected: 0.5 da precursor mass tolerance,
monoisotopic mass, semi-tryptic search with two or fewer missed
cleavages, oxidized methionine, deamidation (Gln, Asn), iTRAQ
label on Tyr, iTRAQ label on Lys and at the peptide N-terminus,
and thiomethyl cysteine were specified as variable modifications.
In total, 8580 SEQUEST search results (all from singly-charged
spectra) were obtained and further processed using PeptideProphet
and ProteinProphet, leading to the identification of 3686 peptides
mapping to 904 proteins. Of these, 3550 peptides were quantified
with post-data normalization, which mapped to 879 proteins. The
estimated FDR using target-decoy strategy was below 0.5% [13].
Statistical analysis of differential protein expression
iTRAQ analysis. Double-duplex iTRAQ experiment
consisting of duplicates of vehicle- and R1881-treated samples
resulted in the identification of 3686 peptides as shown above.
Quantitative information for each peptide identified was extracted
from the MS/MS spectrum using Libra, available as a part of the
Trans-Proteomic Pipeline. Based on the distribution pattern of
peak areas of tags 114, 115, 116 and 117 for all the peptides, a
median centered normalization was applied at the peptide level to
achieve a mean close to unity. Peptides with no value for peak area
(peak intensity below a default threshold in Libra) in any of the
tagged channels were removed. Outlier peptides that had iTRAQ
values three standard deviations (SD) away from the population
median were considered abnormal and were removed from
controls (114 vs. 116) or treatments (115 vs. 117). This procedure
resulted in a final set of 3550 peptides mapping to 879 proteins.
The relative protein expression ratios were then determined with
respect to the first control sample (tag 114). Intensities of peaks at
115, 116 and 117 were divided by the 114 peak intensity, and the
ratios of all peptides corresponding to the same proteins were
averaged. The resulting protein ratios were again normalized by
their population median. The standard deviation of the control
replicate (tag 116, SD=0.16) was used as a scale to set the
threshold ratio for differentially expressed proteins. A minimum
threshold of 1.25 SD (ratio of 1.2 for up-regulated and 0.83 for
down-regulated) from the global mean in both androgen-treated
samples and not less than 1.5 SD in one of the androgen treated
samples (1.25 and 0.8 for up- and down-regulated, respectively)
were considered as androgen regulated.
MudPIT analysis. Proteins identified in the two separate
mass spectrometry runs (control vs. androgen treated) were
combined into a single list, and ambiguities resulting from
protein isoforms and multiple accession numbers [34] were
resolved using in-house software. For each protein in the
combined list (or protein group with multiple accession
numbers), the total number of MS/MS spectra, which were
assigned to peptides was calculated. The spectrum count measures
for each protein were normalized. The normalization was done to
account for small differences in the number of identified peptides
in each analysis. Normalization factor was taken as the total
number of spectra observed in each experiment that were assigned
a peptide, from a protein identified in both experiments with high
probability. For proteins that were identified in both experiments,
the ratio of normalized spectrum counts was calculated and then
log-transformed. The resulting distribution was fitted using a
robust Gaussian distribution fitting procedure with outlier removal
(10% of the data), and the mean and standard deviation (SD) were
determined. Two-SD threshold was applied to derive the list of
differentially expressed proteins. Consequently, the final
established requirement was that, if the protein were identified
by a single MS/MS spectrum in one of the experiments, it should
be identified by four or more spectra in the other experiment.
Similarly, a threshold of four or more spectra was applied to
proteins identified in one of the runs only.
Western. Proteins for immunoblotting were resolved by 4–
12% NUPAGE gels (Invitrogen) and transferred to PVDF
membranes (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ). Membranes were then blocked with 5% skimmed milk in
TBS-T (20 mM Tris.Cl, pH 7.4, 150 mM NaCl, 0.1 % Tween 20)
over-night. Antibodies (indicated in ‘Materials’) were added in
TBS-T containing 2.5% skimmed milk and the blots were washed
with TBST (TBS +0.1% Tween 20). Immunoblot signals were
developed using enhanced chemiluminescence reagent (ECL plus,
GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Western
band intensity ratios were calculated using the ‘ImageJ’ software
version 1.38 (rsb.info.nih.gov/ij/)
Immunofluorescence and confocal microscopy. Control
and R1881 treated cells were fixed on glass slides. Slides were
heated in citrate buffer (pH 6.0) for 15 minutes in a pressure
cooker. The slides were then blocked in PBS-T with 5% normal
donkey serum for 1 hour. A mixture of rabbit anti-AR antibody
(Labvision, Fremont, CA) and mouse anti-FASN antibody (BD
Transduction Labs, Franklin Lakes, NJ) was added to the slides
and incubated overnight at 4uC. Slides were then incubated with
secondary antibodies (anti-rabbit Alexa 555 and anti-mouse
Alexa-486 (Invitrogen) at 1:1000 dilution for 1 hour. They were
washed and then mounted using Vectashield mounting medium.
Confocal images were taken with a Ziess LSM510 META imaging
system using Argon and Helium Neon 1 and Helium Neon 2 light
sources (Carl Zeiss, Thornwood, NY). The wavelengths used were
486 nm and 555 nm for Alexa-486 and Alexa-555, respectively.
Color images were exported as TIFF images.
Oncomine and Molecular Concepts Mapping analyses.
Methods used to identify gene signatures in the Molecular Concepts
Mapping (MCM) tool are described elsewhere [23]. A‘‘molecular
concept’’ is defined as a set of genes or proteins specific to a biological
process or a regulatory mechanism or a particular diseaserepresented
by previously well characterized data sets. Currently, MCM has a
total of 13364 such concepts consisting of 17 types that are derived
f r o m1 3s o u r c e si n c l u d i n gt h ep r o s t a t ec a n c e rg e n ee x p r e s s i o n
signatures from Oncomine database [26]. For our analysis we used all
concept types except the ‘Connectivity map’, and ‘Oncomine
clusters’ [26]. All of our protein data sets were loaded into
Oncomine, and analyzed through the Oncomine linked MCM
[23,26]. MCM computes Fisher’sexact test for each pair of molecular
concepts for association. All results that had an odds ratio greater
than 1.25 and p-value of less than 0.01 were stored. Network maps
were obtained between the selected enriched concepts in our protein
sets and visualized using the MCM. From Oncomine ‘Cancer
Signature’ type concepts, only the top 1%, 5% or 10% gene set
concepts were included in our networks. For network analysis, we
selected the most significant concept, at least one most significant
concept from each concept type that was associated, and any concept
that showed relevance to prostate cancer or androgen treatment.
Meta-analysis of our proteomics data and the prostate cancer tissue
microarray data was performed using MCM [26], and the heat map
was visualized with the genes ranked based on their P- values. Three
data sets used for the heat map were: 1) Lappointe (normal prostate, 41
samples vs. prostate cancer, 62 samples); 2) Welsh (normal prostate, 9
samples vs. prostate cancer, 25 samples); 3) LaTulippe (non-neoplastic
prostate, 3 samples vs. prostate carconima, 23 samples).
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immunoprecipitation was performed according to the published
protocol [35]. Polyclonal antibody to AR (PG-21, Upstate, NY,
USA) was used for immunoprecipitation on the control (vehicle
treated) and androgen treated LNCaP cell nuclear lysates. For
PCR analysis of target gene enrichment analysis, 2 ml of input
DNA, and target-enriched DNA were used. PCR primer
sequences designed to flank the target gene promoters and used
for ChIP-PCR are given in Supplementary Table S5.
Supporting Information. Two supplementary figures, and
five supplementary tables. This material is available free at http://
pubs.plosone.org.
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